Get access

Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia

Authors

  • J. E. Tomassini,

    1. Clinical and Quantitative Sciences, Merck & Co., Inc., North Wales, PA, USA
    Search for more papers by this author
  • T. Mazzone,

    1. Department of Medicine, Section of Endocrinology, Diabetes and Metabolism, University of Illinois at Chicago, Chicago, IL, USA
    2. Department of Pharmacology, Section of Endocrinology, Diabetes and Metabolism, University of Illinois at Chicago, Chicago, IL, USA
    Search for more papers by this author
  • R. B. Goldberg,

    1. Diabetes Research Institute, Leonard M. Miller School of Medicine, Department of Medicine, University of Miami, Miami, FL, USA
    Search for more papers by this author
  • J. R. Guyton,

    1. Department of Medicine, Duke University Medical Center, Durham, NC, USA
    Search for more papers by this author
  • R. S. Weinstock,

    1. Joslin Diabetes Center and Division of Endocrinology, Diabetes and Metabolism, SUNY Upstate Medical University, Syracuse, NY, USA
    2. Department of Veterans Affairs Medical Center, Syracuse, NY, USA
    Search for more papers by this author
  • A. Polis,

    1. Clinical and Quantitative Sciences, Merck & Co., Inc., North Wales, PA, USA
    Search for more papers by this author
  • E. Jensen,

    1. Clinical and Quantitative Sciences, Merck & Co., Inc., North Wales, PA, USA
    Search for more papers by this author
  • A. M. Tershakovec

    Corresponding author
    1. Clinical and Quantitative Sciences, Merck & Co., Inc., North Wales, PA, USA
      Dr Andrew Tershakovec, MD, MPH, Merck & Co., Inc., UG3D-08, 351 N. Sumneytown Pike, North Wales, PA 19454-2525, USA.
      E-mail:
      andrew_tershakovec@merck.com
    Search for more papers by this author

Dr Andrew Tershakovec, MD, MPH, Merck & Co., Inc., UG3D-08, 351 N. Sumneytown Pike, North Wales, PA 19454-2525, USA.
E-mail:
andrew_tershakovec@merck.com

Abstract

Aim: To evaluate the effects of the usual starting and next higher doses of ezetimibe/simvastatin and atorvastatin on the cholesterol content of lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia.

Methods: This post hoc analysis compared the effects of treatment with ezetimibe/simvastatin 10/20 mg vs. atorvastatin 10 and 20 mg/day and ezetimibe/simvastatin 10/40 mg/day vs. atorvastatin 40 mg/day on the cholesterol content of lipoprotein subclasses in the modified intent-to-treat (mITT) population (n = 1013) and in subgroups of patients with triglyceride (TG) levels <200 mg/dl (n = 600) and ≥200 mg/dl (2.6 mmol/l) (n = 413).

Results: Ezetimibe/simvastatin significantly reduced low-density lipoprotein cholesterol (LDL-C) subclasses LDL1-C, LDL2-C and LDL3-C; real LDL-C (LDL-Cr); intermediate-density lipoprotein cholesterol (IDL-C), IDL1-C, IDL2-C; very low-density lipoprotein cholesterol (VLDL-C), VLDL3-C; and remnant-like lipoprotein cholesterol (RLP-C) from baseline more than atorvastatin at all dose comparisons (p < 0.01) in the mITT population. Significant improvements were also observed in high-density lipoprotein cholesterol (HDL-C) subclass HDL3-C at the ezetimibe/simvastatin 10/20 mg vs. atorvastatin 20 mg and highest dose comparisons (p < 0.001) and in VLDL1 + 2-C at the lowest and highest dose comparisons (p < 0.001). Changes in LDL4-C and LDL-C subclass patterns (A, B and I) were comparable for both treatments. Generally, similar results were observed for patients with TG levels <200 and ≥200 mg/dl (2.3 mmol). For both treatments, notable differences between TG subgroups were that patients with elevated TGs had smaller reductions in LDL2-C, slightly smaller decreases in all IDL subclasses and greater decreases in all VLDL-C subclasses than those with lower TG levels. Frequency of pattern B was also reduced more in patients with higher TGs for both treatments.

Conclusions: Ezetimibe/simvastatin reduced the cholesterol content of most lipoprotein subclasses from baseline with generally similar efficacy in patients with low and high TGs. Despite the different mechanism of action of ezetimibe, the response to ezetimibe/simvastatin and atorvastatin treatment related to these lipoprotein subclasses was generally consistent with the overall effects of these therapies on the major lipid/lipoprotein classes. The clinical significance of these results awaits further study.

Get access to the full text of this article

Ancillary